Women in biotechnology and health care fields are well represented on Indianapolis Business Journal's Women of Influence list this year. Among the honorees profiled: Roche Diagnostics Vice President of Global Regulatory Policy Danelle Miller, Eli Lilly and Co. Director of Global Health Philanthropic Initiatives Courtney Roberts, Eli Lilly Senior Vice President Christi Shaw, Purdue University Dean of Agriculture Karen Plaut, State Health Commissioner Kristina Box and Anthem CEO Gail Boudreaux.
Joanne Kotz, co-founder and president of Jnana Therapeutics, was named permanent CEO of the biotech company. Interim CEO Amir Nashat says Kotz has built "a talented team and a collaborative, empowering culture, while also leading important work to validate Jnana's proprietary drug discovery platform."
Forbes' 2019 list of 30 movers and shakers younger than 30 includes Broad Institute scientist Catherine Freije, Venrock investment professional Megan Blewett, Nest.Bio founder Cheryl Cui and Thiel fellow Erin Smith. The 18-year-old Smith is a #BuiltByGirls Future Founder competition winner and is working with The Michael J. Fox Foundation on a platform to identify early signs of Parkinson's disease.
Pharma companies should show the cost of a drug in ads, said 77% of people older than 65 surveyed by Wells Fargo Securities. Only 40% of respondents ages 18 to 24 said they wanted drug companies to give prices in ads.
Using the emotional triggers of fear and hope in health care advertising motivates consumers, according to the 2018 Wunderman Health Inertia Study. The health care industry educates consumers but is not doing as well in creating content that compels consumers to act, said Becky Chidester, CEO of Wunderman Health.
Bayer's digital media buying will be handled in-house by 2020 as the company seeks to increase performance and decrease the costs of agency fees and buys, said Josh Palau, vice president of digital strategy and platforms. The internal marketing team will be made up of at least 20 people who will handle planning and strategy.
A measure that would repeal the medical device tax could garner over 60 votes in the Senate during the lame-duck session, AdvaMed President and CEO Scott Whitaker said. "[O]ur focus is going to be laser-like on full repeal and full repeal only. If it doesn't get done this year, then we will reassess where we are and talk about an alternative approach," Whitaker said.
Boston Scientific is planning a restructuring program from 2019 to 2021 and to cut operating annual expenses by up to $150 million and improve performance. The company expects a relatively unchanged total headcount after completion of the program.
A round of financing has brought in $29 million for RenalytixAI, a UK-based company that makes artificial intelligence-enabled diagnostics for kidney disease. The proceeds will be used to develop and commercialize two product categories for early kidney disease detection and kidney transplant rejection management.
The European Investment Bank has provided the final $4.52 million tranche of a three-year project, valued at approximately $17 million, to Finland-based molecular diagnostics firm Mobidiag. The financing, provided under the InnovFin - EU Finance for innovators, has already supported the finalization, launch and commercialization of the company's Novodiag molecular diagnostic system and has allowed the company to develop the Novodiag Bacterial GE+ and Novodiag C. difficile assays for detecting gastrointestinal infections.